STING1 and neoplasm: Moreover, selective activation of STING in cancer cells can produce chemokines and cytokines for recruiting tumor-infiltrating lymphocytes, priming CTLs, and sensitizing originally “cold” (low immunogenicity) tumors to immune checkpoint blockade therapy (18).